Propylcathinone
| Clinical data | |
|---|---|
| Other names | PC; PrC; 2-(Propylamino)propanophenone; α-Propylaminopropiophenone; PAP; N-Propylcathinone; β-Keto-N-propylamphetamine; N-Pr-CAT; PAL-359; PAL359 |
| Drug class | Stimulant; Monoamine releasing agent; Monoamine reuptake inhibitor |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C12H17NO |
| Molar mass | 191.274 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Propylcathinone (code name PAL-359), or N-propylcathinone, is a stimulant and designer drug of the amphetamine and cathinone families.[1][2][3] It is known to be inactive as a dopamine reuptake inhibitor and releasing agent.[3] Nonetheless, the drug substitutes for dextroamphetamine in animal drug discrimination tests.[1] The related agent propylamphetamine is known to be partially metabolized into amphetamine and this is thought to be involved in its effects.[4][5] Propylcathinone was first encountered as a novel designer drug in Europe by 2015.[6][7][2]
See also
References
- ^ a b Dal Cason TA, Young R, Glennon RA (December 1997). "Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs". Pharmacology, Biochemistry, and Behavior. 58 (4): 1109–1116. doi:10.1016/s0091-3057(97)00323-7. PMID 9408221.
- ^ a b Pulver B, Fischmann S, Gallegos A, Christie R (December 2024). "EMCDDA framework and practical guidance for naming cathinones". Drug Testing and Analysis. 16 (12): 1409–1435. doi:10.1002/dta.3662. PMC 11635063. PMID 38389255.
- ^ a b Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, et al. (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence. 147: 1–19. doi:10.1016/j.drugalcdep.2014.12.005. PMC 4297708. PMID 25548026.
- ^ Beckett AH, Shenoy EV (October 1973). "The effect of N-alkyl chain length of stereochemistry on the absorption, metabolism and during excretion of N-alkylamphetamines in man". The Journal of Pharmacy and Pharmacology. 25 (10): 793–799. doi:10.1111/j.2042-7158.1973.tb09943.x. PMID 4151673.
- ^ Coutts RT, Dawson GW, Beckett AH (November 1976). "In vitro metabolism of 1-phenyl-2-(n-propylamino) propane (N-propylamphetamine) by rat liver homogenates". The Journal of Pharmacy and Pharmacology. 28 (11): 815–821. doi:10.1111/j.2042-7158.1976.tb04063.x. PMID 11289.
- ^ "2015 Annual Reports on the implementation of Council Decision 2005/387/JHA". Europol. 23 October 2018. Retrieved 12 March 2025.
- ^ Błażewicz A, Bednarek E, Popławska M, Olech N, Sitkowski J, Kozerski L (2019). "Identification and structural characterization of synthetic cathinones: N-propylcathinone, 2,4-dimethylmethcathinone, 2,4-dimethylethcathinone, 2,4-dimethyl-α-pyrrolidinopropiophenone, 4-bromo-α-pyrrolidinopropiophenone, 1-(2,3-dihydro-1H-inden-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one and 2,4-dimethylisocathinone" (PDF). Forensic Toxicology. 37 (2): 288–307. doi:10.1007/s11419-018-00463-w. ISSN 1860-8965. Retrieved 12 March 2025.